What is Immatics N.V. (IMTX) stock price today?

Immatics N.V. (IMTX) is currently trading at $7.43, up 0.81% today.

What is IMTX P/E ratio?

Immatics N.V.'s P/E ratio is -4.33. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IMTX return on equity (ROE)?

Immatics N.V.'s return on equity (ROE) is -47.04%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Immatics N.V.'s market cap?

Immatics N.V. has a market capitalization of $996.34M.

NASDAQ · Biotechnology

Immatics N.V. (IMTX) Stock

$7.43 +0.81% NASDAQ: IMTX Healthcare

Valuation

Metric	Value
Price	$7.43
Market Cap	$996.34M
P/E Ratio	-4.33
P/B Ratio	2.36
P/S Ratio	22.14
EPS (TTM)	$-1.78
52-Week High	$12.41
52-Week Low	$7.14
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-47.04%
ROA	-42.54%
ROCE	-52.91%
Gross Margin	100.00%
Operating Margin	-5.70%
Net Margin	-495.27%
Debt/Equity	0.04
Current Ratio	11.72

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$35.0M	$173.0M	$54.0M	$156.0M	$48.0M
Operating Profit	$-86.0M	$30.0M	$-102.0M	$-39.0M	$-182.0M
Net Profit	$-93.0M	$28.0M	$-95.0M	$15.0M	$-196.0M
EPS	$-1.48	$0.55	$-1.18	$0.14	$-1.54
Op Margin	-248.2%	17.3%	-188.4%	-24.8%	-377.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$175.0M	$408.0M	$510.0M	$696.0M	$562.0M
Total Liabilities	$151.0M	$204.0M	$292.0M	$121.0M	$78.0M
Cash	$133.0M	$149.0M	$218.0M	$237.0M	$346.0M
Borrowings	$10.0M	$15.0M	$15.0M	$16.0M	$16.0M

Latest News

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting GlobeNewswire · Jun 1, 2026 Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer GlobeNewswire · May 31, 2026 Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting GlobeNewswire · May 30, 2026 Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results Simply Wall St. · May 15, 2026 Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 12, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-82.0M	$100.0M	$18.0M	$-158.0M	$-170.0M
Investing Cash Flow	$2.0M	$-216.0M	$-62.0M	$-169.0M	$190.0M
Financing Cash Flow	$0	$-8.0M	$-2.0M	$-21.0M	$-3.0M
Net Cash Flow	$-75.0M	$16.0M	$70.0M	$18.0M	$137.0M
Free Cash Flow	$-87.0M	$94.0M	$-13.0M	$-175.0M	$-176.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.05
EV / EBITDA	-3.64
FCF Yield	-22.74%
Quick Ratio	7.54
Interest Coverage	-261.27
Return 1Y	44.03%
Return 3Y	-23.79%
Return 5Y	-21.56%

Ownership

Insiders Held17.58%

Institutions Held79.47%

Institutions Float Held96.42%

Institutional Holder	Shares	Report Date
T. Rowe Price Investment Management, Inc.	21,652,162	2026-03-31
RTW Investments LP	12,869,340	2026-03-31
Suvretta Capital Management, LLC	11,190,129	2026-03-31
Baker Bros. Advisors, LP	10,916,693	2026-03-31
Perceptive Advisors Llc	10,383,456	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLOAllogene Therapeutics, Inc.	$1.46	+4.29%	-2.24	$503.93M	0.00%
ATRAAtara Biotherapeutics, Inc.	$9.48	+2.71%	-7.94	$85.42M	0.00%
BNTXBioNTech SE	$90.07	-1.55%	-15.45	$22.78B	0.00%
CLLSCellectis S.A.	$2.81	-2.26%	-4.14	$282.17M	0.00%
DTILPrecision BioSciences, Inc.	$6.72	+4.51%	-2.26	$185.48M	0.00%

About Immatics N.V.

Immatics N.V. is led by CEO Harpreet Singh, employs 554 people, headquartered in DE, publicly traded since 2018.

Immatics N.V. (IMTX) stock trades at $7.43 with a market capitalization of $996.34M. The stock is valued at a price-to-earnings (P/E) ratio of -4.33, price-to-book of 2.36, price-to-sales of 22.14. Over the past 52 weeks the stock has ranged between $7.14 and $12.41, and currently trades 40.1% below its 52-week high.

On profitability, Immatics N.V. generates a return on equity (ROE) of -47.04%, return on capital employed of -52.91%, an operating margin of -5.70%, a net profit margin of -495.27%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides